Bayer Presented New Analyses Investigating KERENDIA® (finerenone) on Cardiovascular Outcomes in Patients With Chronic Kidney Disease Associated With Type 2 DiabetesBusiness Wire • 11/18/21
Bayer, Microsoft Enter Into Strategic Partnership to Optimize and Advance Digital Capabilities for Food, Feed, Fuel, Fiber Value ChainBusiness Wire • 11/17/21
Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21
Effective January 1, 2022: Rodrigo Santos Named Member of the Board of Management, Bayer AG, and President of the Crop Science DivisionBusiness Wire • 11/09/21
Bayer Pharmaceuticals and The Life Raft Group, a Non-Profit, Announce Innovative Collaboration to Accelerate Cancer Research for GIST PatientsBusiness Wire • 11/08/21
Bayer Presents New Subgroup Analysis of Prespecified Pooled Analysis of Phase III Studies for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without SGLT2i Use at BaselineBusiness Wire • 11/08/21
Bayer Consumer Health Media Team Named AdExchanger Winner for Best In-House Media OperationsBusiness Wire • 11/03/21
Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA® (finerenone)Business Wire • 10/27/21
Bayer fuels leading market positions in Crop Science through delivery of unmatched innovationBusiness Wire • 10/19/21
Bayer Appoints New General Managers for Nutritionals and Digestive Health BusinessesBusiness Wire • 10/05/21